Trion Pharma GmbH
Records under this name other than patents Trion Pharma GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Trion Pharma GmbH
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,709,421 | Combination of the application of antibodies for immunostimulation together with glucocorticoids Formerly held In force · High confidence | In force | High confidence | |
| US 9,017,676 | Destruction of tumor cells by trifunctional bispecific antibodies with low to medium expression levels of tumor-associated target antigens Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,605,242 | Removal of tumor cells from intraoperative autologous blood salvage Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,663,638 | Intraoperative trifunctional antibody application for prophylaxis of intraperitoneal tumor cell dissemination Formerly held Lapsed on the fee record Ended Mar 4, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 4, 2026 | From the USPTO record |
| US 8,066,989 | Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy Formerly held Term ended Term ended Nov 26, 2025 · From the USPTO record | Term ended | Term ended Nov 26, 2025 | From the USPTO record |
| US 8,277,806 | Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites Formerly held Lapsed on the fee record Ended Oct 2, 2020 · From the USPTO record | Lapsed on the fee record | Ended Oct 2, 2020 | From the USPTO record |
| US 6,994,853 | Time-staggered utilization of tumor cells in combination with intact antibodies for immunization Lapsed on the fee record Ended Feb 7, 2014 · From the USPTO record | Lapsed on the fee record | Ended Feb 7, 2014 | From the USPTO record |